Angiotensin-converting enzyme inhibitors and the risk of congenital malformations
BT Bateman, E Patorno, RJ Desai… - Obstetrics & …, 2017 - journals.lww.com
OBJECTIVE: To examine the association between first-trimester angiotensin-converting
enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and …
enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and …
Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations
BT Bateman, E Patorno, RJ Desai… - Obstetrics & …, 2017 - ingentaconnect.com
OBJECTIVE: To examine the association between first-trimester angiotensin-converting
enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and …
enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and …
Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations
BT Bateman, E Patorno, RJ Desai, EW Seely… - Obstetrics and …, 2017 - hero.epa.gov
OBJECTIVE: To examine the association between first-trimester angiotensin-converting
enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and …
enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and …
Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations
BT Bateman, E Patorno, RJ Desai… - Obstetrics and …, 2017 - pubmed.ncbi.nlm.nih.gov
Objective To examine the association between first-trimester angiotensin-converting enzyme
(ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and central …
(ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and central …
Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations.
BT Bateman, E Patorno, RJ Desai… - Obstetrics and …, 2017 - europepmc.org
Objective To examine the association between first-trimester angiotensin-converting enzyme
(ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and central …
(ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and central …
[HTML][HTML] Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations
BT Bateman, E Patorno, RJ Desai… - Obstetrics and …, 2017 - ncbi.nlm.nih.gov
Objective To examine the association between first-trimester angiotensin-converting enzyme
(ACE) inhibitor exposure and the risk for overall major congenital, cardiac, and central …
(ACE) inhibitor exposure and the risk for overall major congenital, cardiac, and central …
Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations
BT Bateman, E Patorno, RJ Desai… - Obstetrics & …, 2017 - journals.lww.com
OBJECTIVE: To examine the association between first-trimester angiotensin-converting
enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and …
enzyme (ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and …
Angiotensin-Converting Enzyme Inhibitors and the Risk of Congenital Malformations.
BT Bateman, E Patorno, RJ Desai… - Obstetrics and …, 2017 - europepmc.org
Objective To examine the association between first-trimester angiotensin-converting enzyme
(ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and central …
(ACE) inhibitor exposure and the risk of overall major congenital, cardiac, and central …